DaVita stock kpis
Want to see DVA full AI Analyst Report?
Operating Profit by Segment
DaVita reported operating profit by segment of $499.25M in Q3 2026, down 13.8% from Q2 2026 and down 1.3% year over year. The highest value was $579.00M in Q2 2026.
Shows the profitability of each business segment, highlighting which areas are driving earnings and where there may be challenges or opportunities for improvement.
Dialysis is the clear profit engine — its operating income has recovered and now drives enterprise OI — while Ancillary Services has flipped from losses to materially positive but remains volatile, suggesting lumpier contributions (IKC/other income and timing effects). Corporate expenses have meaningfully moderated recently, aiding margin recovery. Management reconfirmed guidance and expects treatment growth near the top of the range, but persistent RPT pressure, ACA mix headwinds and elevated patient‑care cost growth pose upside risk unless volume and cost trends sustain.
DVA Operating Profit by Segment
| Period | Corporate | Dialysis | Ancillary Services | Total |
|---|---|---|---|---|
| Q3 2026Sep 30, 2026 | -$26.28M | $544.18M | -$18.64M | $499.25M |
| Q2 2026Jun 30, 2026 | -$16.00M | $538.00M | $57.00M | $579.00M |
| Q1 2026Mar 31, 2026 | -$30.00M | $506.00M | $6.00M | $482.00M |
| Q4 2025Dec 31, 2025 | -$32.00M | $556.00M | $37.00M | $561.00M |
| Q3 2025Sep 30, 2025 | -$25.57M | $530.11M | $1.22M | $505.77M |
| Q2 2025Jun 30, 2025 | -$42.00M | $523.00M | $57.00M | $538.00M |
| Q1 2025Mar 31, 2025 | -$34.00M | $476.00M | -$3.00M | $439.00M |
| Q4 2024Dec 31, 2024 | -$29.00M | $496.00M | $100.00M | $567.00M |
| Q3 2024Sep 30, 2024 | -$29.00M | $549.00M | $14.00M | $534.00M |
| Q2 2024Jun 30, 2024 | -$25.00M | $550.00M | -$19.00M | $506.00M |
| Q1 2024Mar 31, 2024 | -$30.00M | $526.00M | -$12.00M | $484.00M |
| Q4 2023Dec 31, 2023 | -$63.00M | $444.00M | $10.00M | $391.00M |
| Q3 2023Sep 30, 2023 | -$41.00M | $509.00M | $28.00M | $496.00M |
| Q2 2023Jun 30, 2023 | -$34.00M | $461.00M | -$22.00M | $405.00M |
| Q1 2023Mar 31, 2023 | -$25.00M | $361.00M | -$25.00M | $311.00M |
| Q4 2022Dec 31, 2022 | -$39.00M | $335.00M | -$41.00M | $255.00M |
| Q3 2022Sep 30, 2022 | -$24.00M | $351.00M | -$15.00M | $312.00M |
| Q2 2022Jun 30, 2022 | -$31.00M | $473.00M | -$9.00M | $433.00M |
| Q1 2022Mar 31, 2022 | -$36.00M | $406.00M | -$32.00M | $338.00M |
| Q4 2021Dec 31, 2021 | -$34.00M | $451.00M | -$29.00M | $388.00M |
| Q3 2021Sep 30, 2021 | -$28.00M | $510.00M | -$7.00M | $475.00M |
| Q2 2021Jun 30, 2021 | -$25.00M | $534.00M | -$18.00M | $491.00M |
| Q1 2021Mar 31, 2021 | -$25.00M | $480.00M | -$12.00M | $443.00M |
| Q4 2020Dec 31, 2020 | -$24.00M | $432.00M | -$26.00M | $382.00M |
| Q3 2020Sep 30, 2020 | -$26.00M | $471.00M | -$7.00M | $438.00M |
| Q2 2020Jun 30, 2020 | -$73.00M | $523.00M | -$40.00M | $410.00M |
| Q1 2020Mar 31, 2020 | -$24.00M | $492.00M | -$3.00M | $465.00M |

